Co‐expression of EGFR mutation‐targeted guide RNA and Streptococcus pyogenes Cas9 (SpCas9) via adenoviral vector would specifically destroy the oncogenic mutation and result in the inhibition of cancer cells growth.[43] In cancer therapy, specifically targeting genomic rearrangements is still an unattainable goal. The gene discussed is EGFR; the disease is cancer.